Idera Pharmaceuticals (United States)

Recent papers from Idera Pharmaceuticals (United States)

1. Effect of the Dual Endothelin Receptor Antagonist Aprocitentan on AlbuminuriaJournal of Hypertension · 2026
2. Daridorexant in severe obstructive sleep apnea: Effects on sleep-disordered breathing and sleepSLEEP · 2026
3. 0460 Efficacy and Safety of Daridorexant in Individuals with Insomnia with Short Sleep Duration and Normal Sleep DurationSLEEP · 2026
4. Real-world data on the abuse potential of medications for the treatment of insomnia: a disproportionality analysis of the FAERS databaseSHILAP Revista de lepidopterología · 2026
5. Space exploration and lifestyle medicine: a narrative review of its implications for astronaut health and remote Earth-based environmentsFrontiers in Physiology · 2026
6. The insomnia EEG score (IES): a new tool for the classification of people with poor sleepSLEEP · 2025
7. Time to therapeutic effect with daridorexant: Weekly analysis of patient-reported outcomes from a Phase 3 randomized, placebo-controlled study in patients with insomnia disorderEuropean Psychiatry · 2025
8. Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorderEuropean Psychiatry · 2025
9. A novel translational in-silico indication discovery framework identifies indications and predictive biomarkers for cenerimod2025
10. The Effects of Daridorexant on Patients With Comorbid Insomnia Disorder and Untreated Mild Obstructive Sleep Apnoea: A Post Hoc Subgroup Analysis of a Phase 3, Randomised Clinical TrialJournal of Sleep Research · 2025
11. Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor2025
12. The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4Xenobiotica · 2025
13. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Journal of Clinical Oncology · 2025
14. Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).Journal of Clinical Oncology · 2024
15. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmedPostgraduate Medicine · 2024
16. 0169 Nighttime Safety of Daridorexant: Response to Noise Stimuli, and Effects on Postural Stability, Walking and MemorySLEEP · 2024
17. 0100 Excretion of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating WomenSLEEP · 2024
18. 0414 Dose-response of Daridorexant in Insomnia Disorder: A Meta-analysis of Phase 2 and 3 StudiesSLEEP · 2024
19. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitorsScience · 2023
20. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor MicroenvironmentMolecular Cancer Therapeutics · 2023